{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T19:32:42Z","timestamp":1791660762494,"version":"4.3.4"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Cardiovascular disease represents the leading cause of mortality among patients with chronic kidney disease (CKD). CKD-associated cardiomyopathy is characterized by pathological left ventricular hypertrophy and myocardial fibrosis. Pegmolesatide, a novel pegylated continuous erythropoietin receptor activator, has demonstrated efficacy in treating renal anemia. However, the biological effects of Pegmolesatide beyond erythropoiesis remain poorly characterized.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study established a 5\/6 nephrectomy rat model of CKD. The animals were randomized into four groups: sham-operated (Sham), sham-operated plus Pegmolesatide (Sham + Pegmolesatide), CKD model (CKD), and CKD model plus Pegmolesatide (CKD + Pegmolesatide). Cardiac function was assessed by echocardiography, while histopathological examination evaluated cardiac and renal structural changes. Serum renal function parameters were measured using biochemical assays. Myocardial expression of proteins and mRNAs related to fibrosis, hypertrophy, and associated signaling pathways was analyzed by Western blot and quantitative PCR. Furthermore, transcriptomic sequencing of myocardial tissue was performed, and in vitro experiments were conducted using AC16 human cardiomyocytes stimulated with serum from stage 5 CKD patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Transcriptomic sequencing suggested that the cardioprotective effects of Pegmolesatide might be associated with improved mitochondrial function and modulation of the STAT3 signaling pathway. Results demonstrated that Pegmolesatide significantly improved cardiac functional parameters and attenuated both myocardial fibrosis and cardiomyocyte hypertrophy. Mechanistic investigations revealed that these cardioprotective effects were mediated through inhibition of JAK2\/STAT3 signaling pathway activation and concomitant improvement of mitochondrial function.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>These findings demonstrate that pegmolesatide exerts anti-anemic effect-independent cardioprotection, offering novel insights into treating CKD-associated cardiomyopathy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1806374","type":"journal-article","created":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T05:53:58Z","timestamp":1778651638000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Amelioration of CKD-induced cardiomyocyte hypertrophy by pegmolesatide: involvement of JAK2\/STAT3 inhibition and mitochondrial protection"],"prefix":"10.3389","volume":"17","author":[{"given":"Xinyu","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Nephrology, Peking University People\u2019s Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sufang","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Beijing Key Laboratory of Early Prediction and Intervention of Acute Myocardial Infarction, Center for Cardiovascular Translational Research, Peking University People\u2019s Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingru","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Peking University People\u2019s Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangying","family":"Gan","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Peking University People\u2019s Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanze","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Basic Medical Sciences, Peking University Health Science Center","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Peking University People\u2019s Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zuo","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Peking University People\u2019s Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1186\/s12964-025-02378-7","article-title":"Elevated levels of Letm1 drives mitochondrial dysfunction and cardiomyocyte stress-mediated apoptosis in cultured cardiomyocytes","volume":"23","author":"Deshpande","year":"2025","journal-title":"Cell Commun. Signal."},{"key":"B2","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/S0140-6736(13)60439-0","article-title":"Evolving importance of kidney disease: from subspecialty to global health burden","volume":"382","author":"Eckardt","year":"2013","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","first-page":"2607","DOI":"10.1111\/jcmm.17267","article-title":"Periplocymarin alleviates pathological cardiac hypertrophy via inhibiting the JAK2\/STAT3 signalling pathway","volume":"26","author":"Fan","year":"2022","journal-title":"J. Cell. Mol. Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"116313","DOI":"10.1016\/j.biopha.2024.116313","article-title":"Targeting the JAK2\/STAT3 signaling pathway with natural plants and phytochemical ingredients: a novel therapeutic method for combatting cardiovascular diseases","volume":"172","author":"Guo","year":"2024","journal-title":"Biomed. and Pharmacother."},{"key":"B5","doi-asserted-by":"publisher","first-page":"3061","DOI":"10.7150\/ijbs.111128","article-title":"Macrophage-derived S100A9 promotes diabetic cardiomyopathy by disturbing mitochondrial quality control via STAT3 activation","volume":"21","author":"Huo","year":"2025","journal-title":"Int. J. Biol. Sci."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1161\/CIRCULATIONAHA.120.050686","article-title":"Cardiovascular disease in chronic kidney disease","volume":"143","author":"Jankowski","year":"2021","journal-title":"Circulation"},{"key":"B7","doi-asserted-by":"publisher","first-page":"226","DOI":"10.3858\/emm.2009.41.4.025","article-title":"Modulation of the caveolin-3 localization to caveolae and STAT3 to mitochondria by catecholamine-induced cardiac hypertrophy in H9c2 cardiomyoblasts","volume":"41","author":"Jeong","year":"2009","journal-title":"Exp. Mol. Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"631","DOI":"10.3390\/ph17050631","article-title":"Patchouli alcohol protects the heart against diabetes-related cardiomyopathy through the JAK2\/STAT3 signaling pathway","volume":"17","author":"Ji","year":"2024","journal-title":"Pharmaceuticals"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e0198196","DOI":"10.1371\/journal.pone.0198196","article-title":"Pathological presentation of cardiac mitochondria in a rat model for chronic kidney disease","volume":"13","author":"Joles","year":"2018","journal-title":"Plos One"},{"key":"B10","doi-asserted-by":"publisher","first-page":"352","DOI":"10.3390\/toxins10090352","article-title":"Cardiotoxicity of uremic toxins: a driver of cardiorenal syndrome","volume":"10","author":"Lekawanvijit","year":"2018","journal-title":"Toxins"},{"key":"B11","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1053\/j.jrn.2014.10.009","article-title":"Cardiorenal syndrome: role of protein-bound uremic toxins","volume":"25","author":"Lekawanvijit","year":"2015","journal-title":"J. Ren. Nutr."},{"key":"B12","doi-asserted-by":"publisher","first-page":"102098","DOI":"10.1016\/j.redox.2021.102098","article-title":"Paeonol promotes Opa1-mediated mitochondrial fusion via activating the CK2\u03b1-Stat3 pathway in diabetic cardiomyopathy","volume":"46","author":"Liu","year":"2021","journal-title":"Redox Biol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"e2414358","DOI":"10.1002\/advs.202414358","article-title":"ECSIT\u2010X4 is required for preventing pressure overload\u2010induced cardiac hypertrophy via regulating mitochondrial STAT3","volume":"12","author":"Lu","year":"2025","journal-title":"Adv. Sci."},{"key":"B14","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/s12967-025-06078-1","article-title":"Overview of preclinical and phase II clinical studies on Pegmolesatide\u2019s long-term erythropoiesis stimulating effect via EPOR-Mediated signal transduction","volume":"23","author":"Ma","year":"2025","journal-title":"J. Transl. Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"101590","DOI":"10.1016\/j.cpcardiol.2023.101590","article-title":"Left ventricular hypertrophy (LVH) and left ventricular geometric patterns in patients with chronic kidney disease (CKD) stage 2-5 with preserved ejection fraction (EF): a systematic review to explore CKD stage-wise LVH patterns","volume":"48","author":"Maqbool","year":"2023","journal-title":"Curr. Problems Cardiol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1080\/14728222.2021.1849145","article-title":"Emerging therapeutic targets for cardiac arrhythmias: role of STAT3 in regulating cardiac fibroblast function","volume":"25","author":"Patel","year":"2020","journal-title":"Expert Opin. Ther. Targets"},{"key":"B17","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/s41581-022-00576-x","article-title":"Cardiac metabolic remodelling in chronic kidney disease","volume":"18","author":"Patel","year":"2022","journal-title":"Nat. Rev. Nephrol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s12276-019-0355-7","article-title":"Mitochondrial dysfunction and oxidative stress in heart disease","volume":"51","author":"Peoples","year":"2019","journal-title":"Exp. and Mol. Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"3706","DOI":"10.3390\/jcm14113706","article-title":"Mitochondrial dysfunction in the development and progression of cardiometabolic diseases: a narrative review","volume":"14","author":"Pliouta","year":"2025","journal-title":"J. Clin. Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"e0158765","DOI":"10.1371\/journal.pone.0158765","article-title":"Global prevalence of chronic kidney disease \u2013 a systematic review and meta-analysis","volume":"11","author":"Remuzzi","year":"2016","journal-title":"Plos One"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1016\/j.jacc.2008.07.051","article-title":"Cardiorenal syndrome","volume":"52","author":"Ronco","year":"2008","journal-title":"J. Am. Coll. Cardiol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"e18978","DOI":"10.7717\/peerj.18978","article-title":"Understanding uremic cardiomyopathy: from pathogenesis to diagnosis and the horizon of therapeutic innovations","volume":"13","author":"Song","year":"2025","journal-title":"PeerJ"},{"key":"B23","doi-asserted-by":"publisher","first-page":"F579","DOI":"10.1152\/ajprenal.00442.2014","article-title":"Mitochondrial dysfunction in uremic cardiomyopathy","volume":"308","author":"Taylor","year":"2015","journal-title":"Am. J. Physiology-Renal Physiology"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.139826","article-title":"Impaired muscle mitochondrial energetics is associated with uremic metabolite accumulation in chronic kidney disease","volume":"6","author":"Thome","year":"2020","journal-title":"JCI Insight"},{"key":"B25","doi-asserted-by":"publisher","first-page":"773","DOI":"10.3390\/biom13050773","article-title":"Cardiac imaging biomarkers in chronic kidney disease","volume":"13","author":"Valbuena-L\u00f3pez","year":"2023","journal-title":"Biomolecules"},{"key":"B26","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/s41581-018-0101-8","article-title":"Evolving concepts in the pathogenesis of uraemic cardiomyopathy","volume":"15","author":"Wang","year":"2019","journal-title":"Nat. Rev. Nephrol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.ekir.2024.12.002","article-title":"Randomized trial of pegmolesatide for the treatment of anemia in patients with nondialysis CKD","volume":"10","author":"Xie","year":"2025","journal-title":"Kidney Int. Rep."},{"key":"B28","doi-asserted-by":"publisher","first-page":"e145475","DOI":"10.1172\/jci.insight.145475","article-title":"Indoxyl sulfate reduces ito,f by activating ROS\/MAPK and NF-\u03baB signaling pathways","volume":"7","author":"Yang","year":"","journal-title":"JCI Insight"},{"key":"B29","doi-asserted-by":"publisher","first-page":"e027004","DOI":"10.1161\/JAHA.122.027004","article-title":"SENP1 protects against pressure overload\u2010induced cardiac remodeling and dysfunction via inhibiting STAT3 signaling","volume":"11","author":"Yang","year":"","journal-title":"J. Am. Heart Assoc."},{"key":"B30","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.molimm.2025.08.018","article-title":"JAK\/STAT pathway in myocardial infarction: crossroads of immune signaling and cardiac remodeling","volume":"186","author":"Yang","year":"2025","journal-title":"Mol. Immunol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1016\/j.lfs.2013.05.008","article-title":"Indoxyl sulfate promotes cardiac fibrosis with enhanced oxidative stress in hypertensive rats","volume":"92","author":"Yisireyili","year":"2013","journal-title":"Life Sci."},{"key":"B32","doi-asserted-by":"publisher","first-page":"10711","DOI":"10.1111\/jcmm.17007","article-title":"PKM2 promotes angiotensin\u2010II\u2010induced cardiac remodelling by activating TGF\u2010\u03b2\/Smad2\/3 and Jak2\/Stat3 pathways through oxidative stress","volume":"25","author":"Zhang","year":"2021","journal-title":"J. Cell. Mol. Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"102273","DOI":"10.1016\/j.eclinm.2023.102273","article-title":"Pegmolesatide for the treatment of anemia in patients undergoing dialysis: a randomized clinical trial","volume":"65","author":"Zhang","year":"2023","journal-title":"eClinicalMedicine"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1806374\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T05:54:01Z","timestamp":1778651641000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1806374\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,13]]},"references-count":33,"alternative-id":["10.3389\/fphar.2026.1806374"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1806374","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,13]]},"article-number":"1806374"}}